Direct Oral Anticoagulants as Alternatives to Apixaban

Pharmacokinetic Properties

The American Heart Association suggests that apixaban has a lower renal clearance (27%) compared to dabigatran (80%) and rivaroxaban (33%), making it potentially preferable in patients with renal impairment 4, 2, 5
The European Heart Rhythm Association guidelines indicate that apixaban has a bioavailability of 50% vs. rivaroxaban 66-100% (with food) vs. edoxaban 62% 4
The American College of Cardiology recommends considering the half-life of DOACs, with apixaban ~12 hours vs. rivaroxaban 5-13 hours vs. dabigatran 12-17 hours 4, 1

The European Society of Cardiology guidelines suggest that rivaroxaban (Xarelto®) has 66% renal excretion and requires once-daily dosing for most indications, with 15-20 mg doses requiring administration with food 1, 2, 5
The American Heart Association recommends that edoxaban (Lixiana®) has 50% renal clearance and once-daily dosing, with dose reduction required for patients with CrCl 15-50 mL/min, weight ≤60 kg, or on P-glycoprotein inhibitors 4, 6
The European Heart Rhythm Association guidelines indicate that dabigatran (Pradaxa®) has 80% renal elimination and requires twice-daily dosing, with significantly higher renal dependence than apixaban 4, 5

The American College of Cardiology suggests that any switch between DOACs should account for indication, renal function, drug interactions, and patient-specific bleeding/thrombotic risk 3, 4
The European Society of Cardiology guidelines recommend considering the food requirements for DOACs, with rivaroxaban 15-20 mg doses requiring administration with food, while apixaban does not require this 4, 1
The American Heart Association guidelines indicate that all four DOACs (dabigatran, rivaroxaban, apixaban, edoxaban) have demonstrated efficacy in stroke prevention for atrial fibrillation, but apixaban demonstrated superior safety with lower major bleeding rates compared to warfarin in the ARISTOTLE trial 3, 7